GlassScriptPhysician profile
Melissa Cameron
NPI 1982076766
$2,336.88
in general payments reported to CMS, 2019-2025
24 companies · $587 in 2025
The $587 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $202 · 2022: $464 · 2023: $514 · 2024: $569 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,656 · Education: $15.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,656.10 |
| Education | $15.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $534.53 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $375.90 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $223.92 | 2022-2025 | Xifaxan |
| Pfizer INC. | $192.53 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $143.05 | 2023-2024 | Farxiga |
| Heartflow, INC. | $111.92 | 2025 | |
| Lilly USA, LLC | $101.92 | 2022-2024 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $85.90 | 2022-2025 | Gvoke Hypopen |
| Avanir Pharmaceuticals, INC. | $79.93 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $78.79 | 2023-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $67.40 | 2021-2024 | |
| Daiichi Sankyo INC. | $52.12 | 2021-2024 | Injectafer |
| Biohaven Pharmaceutical Holding Company LTD. | $42.64 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.45 | 2022-2024 | |
| Dexcom, INC. | $34.15 | 2023 | Dexcom G6 Transmitter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $28.34 | 2022-2024 | Repatha, Otezla |
| Tactile Systems Technology INC | $24.09 | 2025 | Flexitouch Plus, Nimbl |
| Abbott Laboratories | $23.14 | 2025 | Eterna |
| Phathom Pharmaceuticals, INC. | $17.76 | 2024 | Voquezna |
| Acadia Pharmaceuticals INC | $17.33 | 2021 | |
| Smith+Nephew, INC. | $16.57 | 2025 | Real Intelligence |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.80 | 2022 | |
| Mylan Specialty L.P. | $13.92 | 2023 | Yupelri |
| Astellas Pharma US INC | $13.78 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Cameron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.